SW-480
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
SW-480 |
Humane Kolon Adenokarzinom Zell-Linie |
300302 |
cryovial |
265,00 |
SW-480 |
Humane Kolon Adenokarzinom Zell-Linie |
330302 |
vital |
335,00 |
| Designation: | SW-480 |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 51 years |
| Gender: | male |
| Tissue: | Colon |
| Morphology: | epithelial |
| Celltype: | adenocarcinoma, colorectal; Dukes' type B |
| Growth Properties: | monolayer |
| Description: | The line is negative for CSAp (CSAp-) and colon antigen 3. The cells are positive for keratin by immunoperoxidase staining. There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution and a C -> T mutation in codon 309 resulting in a Pro -> Ser substitution. The cells express elevated levels of p53 protein. The line is positive for expression of c-myc, K-ras, H-ras, N-ras, myb, sis and fos oncogenes. N-myc oncogene expression was not detected. Matrilysin, a metalloproteinase associated with tumor invasiveness, is not expressed. The cells have been reported to produce GM-CSF. This line has a mutation in codon 12 of the ras protooncogene, and can be used as a positive control for PCR assays of mutation in this codon. |
| Culture Medium: | Leibovitz's L-15 medium supplemented with 2 mM L-glutamine and 10% fetal bovine serum. Alternatively, Ham's F12 medium supplemented with 2 mM L-glutamine and 5-10% fetal bovine serum may be used. |
| Subculturing: | Remove medium and rinse with 0.02% EDTA-solution. Add fresh 0.025% trypsin/0.02% EDTA for 1-2 minutes, remove the trypsin solution and let the culture sit at 37°C until the cells detach. Add fresh medium, centrifuge, resuspend in fresh medium and dispense into new flasks. |
| Split Ratio: | A ratio of 1:2 to 1:8 is recommended |
| Fluid Renewal: | 1 to 2 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice |
| Oncogene: | myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src - |
| DNA Profile (STR): | Amelogenin: X,X CSF1PO: 13,14 D13S317: 12 D16S539: 13 D5S818: 13 D7S820: 8 THO1: 8 TPOX: 11 vWA: 16 D3S1358: 15 D21S11: 30,30.2 D18S51: 13 Penta E: 10 Penta D: 9,15 D8S1179: 13 FGA: 24 CLS ∙ Cell Lines Service, 2010. |
| Antigen Expression: | HLA A2, B8, B17; blood type A; Rh+ |
| Receptors Expressed: | epidermal growth factor (EGF) |
| Isoenzymes: | G6PD, B; PGM1, 2; PGM3, 1; 6PGD, A; PEP-D, 1; ES-D, 1 |
| Reverse Transcriptase: | negative |
| Virus Susceptibility: | human immunodeficiency virus (HIV, LAV) |
| Products: | carcinoembryonic antigen (CEA) 0.7 ng/106 cells/10 days; keratin; transforming growth factor beta |
References: Leibovitz A et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-9, 1976. Fogh J et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-14, 1977. Fogh J et al. One-hundred and twenty-seven cultured human tumor cells producing tumors in nude mice. J Natl Cancer Inst 59: 221-6, 1977. Lelbovitz A et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J Natl Cancer Inst 63: 635-45, 1979. Adachi A et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol 61: 209-13, 1987. Trainer DL et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 41: 287-96, 1988. Nigro JM et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-8, 1989. Geiser AG et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res 49: 1572-7, 1989. Rodrigues NR et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-9, 1990. Barnett SW et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-9, 1991. Weiss J et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 54: 693-9, 1993. Lahm H et al. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res 54: 3700-2, 1994. Schroy PC 3rd et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 76: 201-9, 1995. Zhu X et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 93: 6091-5, 1996. Santoro IM et al. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res 57: 488-94, 1997. Tsao H et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res 58: 109-13, 1998. Clement PM et al. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 273: 1102-14, 2006. Xie JT et al. Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells. Exp Oncol 28: 25-9, 2006. | |
